The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy, the researchers said.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
